Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKR) Long-Term Investments (2023 - 2025)

Bruker posted quarterly Long-Term Investments of $11.1 million for Q4 2025, down 90.23% year-on-year from $113.6 million in Q4 2024, and down 90.23% on a QoQ basis from $113.6 million in Q4 2024.

Bruker (BRKR) has 3 years of Long-Term Investments data on file, last reported at $11.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 90.23% year-over-year to $11.1 million; the trailing twelve-month figure through Dec 2025 stood at $11.1 million (down 90.23% YoY), and the FY2025 full-year result was $11.1 million, down 90.23% from the prior year.
  • Long-Term Investments for Q4 2025 stood at $11.1 million, down from $113.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $113.6 million in Q4 2024 and bottomed at $8.3 million in Q4 2023.
  • The 3-year median for Long-Term Investments is $11.1 million (2025), against an average of $44.3 million.
  • The widest annual swing landed in 2024, when Long-Term Investments soared 1268.67%; it then slumped 90.23% in 2025.
  • A 3-year view of Long-Term Investments shows it stood at $8.3 million in 2023, then jumped by 1268.67% to $113.6 million in 2024, then plunged by 90.23% to $11.1 million in 2025.
  • The last three Long-Term Investments figures came in at $11.1 million (Q4 2025), $113.6 million (Q4 2024), and $8.3 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.09 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 285.60 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 166.25 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bruker 8.89 Bn 8.77 Bn 379.80 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 11.10 Mn
Dec 31, 2024 113.60 Mn
Dec 31, 2023 8.30 Mn